Immune checkpoint inhibitors, such as PD-1 inhibitors (nivolumab, pembrolizumab, cemiplimab), CTLA-4 inhibitor (ipilimumab), and PD-L1 inhibitors (atezolizumab, durvalumab, avelumab), have transformed cancer treatment by helping the immune system recognize and attack cancer cells (9, 15–24). Here, CTLA4 is linked to cancer.